Bayer gets €3 billion from Apollo for contraceptives unit

• Bayer will maintain majority ownership and complete operational control of the LARC business, which remains part of the pharmaceuticals division and fully consolidated in group accounts
• The €3 billion injection is designed to enhance financial flexibility as Bayer faces increased liquidity requirements this year related to bond maturities and litigation procedures
• The deal is expected to close in the third quarter of 2026, subject to antitrust approval and customary conditions

Summary

Deal Structure:

Bayer has secured €3 billion ($3.4 billion) in equity financing from Apollo-managed funds through a transaction involving its long-acting reversible contraceptives (LARC) business. Apollo will acquire a minority, non-controlling stake in a newly formed entity housing the LARC business, while Bayer retains majority ownership and complete operational control.

Strategic Rationale:

CFO Judith Hartmann described the transaction as a "strategic financing solution" designed to strengthen Bayer's balance sheet and enhance financial flexibility. The move addresses increased liquidity requirements stemming from bond maturities and ongoing litigation procedures in 2026.

Operational Impact:

The LARC business will remain part of Bayer's pharmaceuticals division's core operations and continue to be fully consolidated in the company's group accounts, preserving strategic integration despite the minority investment.

Timeline and Conditions:

The deal is expected to close in Q3 2026, pending antitrust approval and customary closing conditions.

Market Implications:

This transaction represents a creative financing approach that allows Bayer to raise significant capital without relinquishing control or diluting existing shareholders through traditional equity issuance. The structure addresses Bayer's well-documented financial pressures from legacy litigation liabilities while maintaining operational continuity in its pharmaceutical business. For Apollo, this provides exposure to the stable contraceptives market with a minority position in an established business unit. The deal reflects increasing private equity interest in carve-out opportunities within large pharmaceutical companies seeking balance sheet optimization.